The Childrens Hospital at Westmead Oncology Unit
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McCowage, Geoffrey B
CARE study, NCT04094610 / 2019-003055-11: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Checkmark Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
Oct 2021 - Oct 2021: Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
Recruiting
1/2
75
Europe, Canada, US, RoW
Oral repotrectinib (TPX-0005), Oral repotrectinib (TPX-0005) capsules, Oral repotrectinib (TPX-0005) oral suspension, repotrectinib
Turning Point Therapeutics, Inc., Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company)
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
09/26
09/27
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Recruiting
N/A
10000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/00
 

Download Options